***PKTX…PKTX Investors..Over the years…Protoki
Post# of 88
(Total Views: 286)
Posted On: 06/20/2018 9:09:52 AM
***PKTX…PKTX Investors..Over the years…Protokinetix has Only gotten more involved in the diversity of the Bio-Tech medical industry…These are some of the hot projects that PKTX’s molecule ..AAGP is involved in…And the comments from the doctors who are heading up these projects…
…Folks…(IMHO)We are invested in a “Kick-Azz” Anti-inflammatory…WHY..Because it Works.. :+)
****The goal will be to determine whether AAGP™ enhances the ex vivo survival and maintenance of multipotent potential in a way that could be used to enhance bone marrow transplantation. “If AAGP™ could enhance survival or, better still, aid in the expansion of stem cells in vitro, this would be of enormous clinical benefit” – said Dr. Kelly McNagny, Professor of Medical Genetics, UBC.
...(Involved in)…Bone marrow transplant monoclonal antibody production and bone marrow recovery Plus the survival/efficacy of engraftment of hematopoietic stem cells, a technical hurdle in cell based therapies for bone marrow transplantation and cancer therapy. University of British Columbia
Dr. Kelly McNagny
****“We are excited about this new joint research collaboration and hope AAGP™ has some of the same positive effects, with respect to cryopreserving immune cells, that it is having on other cell lines,” says Jeff Schulz, CEO, Proactive Immune Sciences.
****“If the findings translate to the clinic in a manner that reflects the preclinical studies, AAGP™ has the potential to substantially improve outcomes in patients receiving islet transplants today, and future stem cell therapies.” said Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet and Living Donor Liver Transplant Programs, Canada Research Chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta.
...(Involved in)…Phase 1 & Phase 2 Clinical Trials Treated Islet Cells in the Treatment of Type 1 Diabetes …His creation of the Edmonton Protocol…University of Alberta… Dr. James Shapiro
****”AAGP™ could be a huge benefit to the future of Pre-clinical and Clinical transplantation medicine,”said Dr. Kevin Gregory-Evans. He added,“AAGP™ will revolutionize transplantation medicine across the board.”
...(Involved in)…Testing on stem cells transplanted in retina tissue published in the Journal of Tissue Engineering and Regenerative Medicine, June 2016. University of British Columbia
Macular degeneration (AMD), stroke and spinal cord injury… Dr. Kevin Gregory
…Folks…(IMHO)We are invested in a “Kick-Azz” Anti-inflammatory…WHY..Because it Works.. :+)
****The goal will be to determine whether AAGP™ enhances the ex vivo survival and maintenance of multipotent potential in a way that could be used to enhance bone marrow transplantation. “If AAGP™ could enhance survival or, better still, aid in the expansion of stem cells in vitro, this would be of enormous clinical benefit” – said Dr. Kelly McNagny, Professor of Medical Genetics, UBC.
...(Involved in)…Bone marrow transplant monoclonal antibody production and bone marrow recovery Plus the survival/efficacy of engraftment of hematopoietic stem cells, a technical hurdle in cell based therapies for bone marrow transplantation and cancer therapy. University of British Columbia
Dr. Kelly McNagny
****“We are excited about this new joint research collaboration and hope AAGP™ has some of the same positive effects, with respect to cryopreserving immune cells, that it is having on other cell lines,” says Jeff Schulz, CEO, Proactive Immune Sciences.
****“If the findings translate to the clinic in a manner that reflects the preclinical studies, AAGP™ has the potential to substantially improve outcomes in patients receiving islet transplants today, and future stem cell therapies.” said Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet and Living Donor Liver Transplant Programs, Canada Research Chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta.
...(Involved in)…Phase 1 & Phase 2 Clinical Trials Treated Islet Cells in the Treatment of Type 1 Diabetes …His creation of the Edmonton Protocol…University of Alberta… Dr. James Shapiro
****”AAGP™ could be a huge benefit to the future of Pre-clinical and Clinical transplantation medicine,”said Dr. Kevin Gregory-Evans. He added,“AAGP™ will revolutionize transplantation medicine across the board.”
...(Involved in)…Testing on stem cells transplanted in retina tissue published in the Journal of Tissue Engineering and Regenerative Medicine, June 2016. University of British Columbia
Macular degeneration (AMD), stroke and spinal cord injury… Dr. Kevin Gregory
(0)
(0)ProtoKinetix, Inc. (PKTX) Stock Research Links
Scroll down for more posts ▼